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Abstract
Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine
kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-
dose TKI (HD-TKI) pulse-exposure is sufficient to irreversibly commit cells to apoptosis. Here, we report a novel mechanism
of prolonged intracellular TKI activity upon HD-TKI pulse-exposure (imatinib, dasatinib) in BCR-ABL-positive cells.
Comprehensive mechanistic exploration revealed dramatic intracellular accumulation of TKIs which closely correlated with
induction of apoptosis. Cells were rescued from apoptosis upon HD-TKI pulse either by repetitive drug wash-out or by
overexpression of ABC-family drug transporters. Inhibition of ABCB1 restored sensitivity to HD-TKI pulse-exposure. Thus, our
data provide evidence that intracellular drug retention crucially determines biological activity of imatinib and dasatinib.
These studies may refine our current thinking on critical requirements of TKI dose and duration of target inhibition for
biological activity of TKIs.
Citation: Lipka DB, Wagner M-C, Dziadosz M, Schno¨der T, Heidel F, et al. (2012) Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to
Apoptosis in CML Cells. PLoS ONE 7(7): e40853. doi:10.1371/journal.pone.0040853
Editor: Alan P. Fields, Mayo Clinic College of Medicine, United States of America
Received April 23, 2012; Accepted June 14, 2012; Published July 16, 2012
Copyright:  2012 Lipka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by research funds granted by the ‘‘Wilhelm-Sander-Stiftung’’ (No 2011.079.1 to FH, DL, and TF) and by the ‘‘Deutsche
Forschungsgemeinschaft’’ (GRK-1167, P17-2 to TF and SFB-854/1, TP20 to TF), and by SA Pathology (Australia) and the National Institute for Health Research
(NIHR) Biomedical Research Centre, UK funding scheme (to JVM). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: DBL and SK received honoraria from Novartis and BMS; FH, TK
and TF received honoraria from Novartis; MCW, MD, TS, MS and CMT have no relevant conflicts of interest to disclose. This does not alter the authors’ adherence
to all the PLoS ONE policies on sharing data and materials.
* E-mail: thomas.fischer@med.ovgu.de
. These authors contributed equally to this work.
Introduction
Chronic myeloid leukemia (CML) is characterized by the
constitutively activated tyrosine kinase BCR-ABL. Treatment of
CML with the small molecule tyrosine kinase inhibitor (TKI)
imatinib stands as a paradigm for clinical efficacy of targeted small
molecule therapy in malignant disease. Imatinib inhibits BCR-
ABL tyrosine kinase activity and has been shown to effectively
target the malignant clone in vitro and in vivo, resulting in a high
percentage of long-term remissions in CML patients. [1] Beyond
CML, TKIs are currently either approved or evaluated in
numerous other hematologic and solid neoplasms and may
become cornerstones of novel treatment strategies in the near
future. [2–4].
Preclinical and clinical data derived from studies using
imatinib and other compounds suggested that candidates for
clinical development should exhibit a sufficiently long plasma
half-life to facilitate persistent target inhibition: continuous
exposure to imatinib concentrations $1 mM for at least 20 h is
necessary to induce apoptosis in BCR-ABL transformed cells
in vitro, and clinical trials demonstrated a close relationship
between imatinib serum trough-levels and clinical response.[5–7]
Finally, the extent of BCR-ABL inhibition, as determined by the
level of CRKL dephosphorylation, correlated with clinical
activity. [8] Therefore, it has been widely accepted that
continuous and complete target inhibition is a prerequisite for
clinical efficacy of TKI treatment.
Recently, this paradigm has been challenged by data obtained
in a clinical trial using the second generation BCR-ABL inhibitor
dasatinib. [9] Dasatinib (serum half-life: 3–5 h) demonstrated
similar clinical activity but less side effects for once daily dosing
with 100 mg as compared to twice daily dosing with 70 mg. [10]
Interestingly, the once daily dosing schedule apparently resulted in
transient inhibition of BCR-ABL kinase activity only, as re-
phosphorylation of the BCR-ABL downstream adaptor protein
CRKL was observed 8 h post dasatinib-dosing. [10,11] In
addition, in vitro and ex vivo studies suggested that high-dose (HD)
pulse-exposure to TKI irreversibly commits BCR-ABL positive
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cells to apoptosis. This effect was evident upon pulse treatment for
only 20 min –4 h.[12–14] It was proposed that depth, rather than
duration of kinase inhibition, is the critical determinant for TKI
efficacy. [12,13] However, the molecular mechanism for apoptosis
induction after HD-TKI pulse-exposure has remained elusive.
In our present work, we demonstrate that dramatic intracellular
drug retention mediates apoptotic cell death upon HD-TKI pulse-
exposure. In line with this, over-expression of ABC transporters
prevented cell death upon HD-TKI pulse-exposure. These
findings will be useful to rethink our current framework of
pharmacokinetic requirements of TKIs for CML and other




Patient blood samples were drawn after written informed
consent was obtained. Experimentation on human material was
performed according to the premises of the Helsinki declaration
and was approved by the local ethics committee (University
Medical Center, Otto-von-Guericke University Magdeburg,
Germany).
Cell-lines and Patient Samples
Hematopoietic Ba/F3 cells (DSMZ, Braunschweig, Germany)
either parental or stably expressing p210-BCR-ABL (Ba/F3-BCR-
ABL) [15] were used. K562 cells were obtained from DSMZ
(Braunschweig, Germany). K562-Dox cells (referred herein as
K562-ABCG1 cells) were kindly provided by J. Melo (Department
of Haematology, Centre for Cancer Biology, University of
Adelaide, Australia). [16] K562-ABCG2 cells were kindly provid-
ed by Sheng Zhou (Division of Experimental Hematology,
Department of Hematology, St. Jude Childrens Research Hospi-
tal, Memphis, USA). [17] Cells were cultured in RPMI1640
containing 4 mM L-glutamine and 10% FCS at 37uC in
humidified air containing 5% CO2. Media for parental Ba/F3
cells was supplemented with 10% WEHI-conditioned media.
Primary CML samples (MNC) as well as CD34+ cells from normal
controls were isolated and stored in liquid nitrogen. Upon
thawing, cells were cultured in RPMI1640 supplemented with
20% FCS, 50 U/ml penicillin, and 50 mg/ml streptomycin.
Reagents
Cells were treated either with dasatinib (Selleck Chemicals LLC,
Houston, TX, USA) or imatinib (kindly provided by Novartis,
Basel, Switzerland). A 10 mM stock solution was prepared in
DMSO and stored at 220uC. Stocks were further diluted in cell
culture medium. The final DMSO concentration was #0.35%,
depending on the inhibitor concentration used. DMSO exposed
cells were used as controls in all experiments. For some
experiments 10 mM of the ABCB1 inhibitor PSC833 (Tocris,
Missouri, USA) were used.
Figure 1. Experimental set-up for analysis of induction of apoptosis upon HD-TKI exposure. (A) Cells were seeded at a density of
56104 cells/ml in a total volume of 2 ml in RPMI 1640 supplemented with 10% FCS. Cells were treated for 2 h with TKI as indicated. Then, cells were
washed twice with 2 ml PBS at room temperature and replated in fresh cell culture media (2 ml final volume). Cells exposed to 0.35% DMSO served as
controls. 24 h after start of TKI exposure percentage of cells in subG1 phase was measured by flow cytometry after propidium iodide staining. (B) To
analyze for residual TKI activity upon HD-TKI pulse exposure, a second and third drug wash-out procedure (each consisting of 262 ml PBS washing)
was performed: Cells were treated with TKI for 2 h. Cells initially pulse-exposed to HD-TKI were washed twice with 2 ml PBS at room temperature and
replated in 2 ml fresh media (density: 56104 cells/ml) as described in (a) (‘‘1x’’). To test for residual TKI-activity, the cell culture supernatant was
transferred to previously untreated cells (‘‘S1’’), which were subsequently incubated for 24 h. Two hours after replating, a second drug wash-out was
performed (262 ml PBS). Cells were again replated in 2 ml fresh media (‘‘2x’’). Again supernatants were transferred to previously untreated cells
(‘‘S2’’). This procedure was repeated for a third time (‘‘3x’’, ‘‘S3’’).
doi:10.1371/journal.pone.0040853.g001
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For Western blotting the following antibodies were used: anti-
pSTAT5 (pY694) (Millipore, Billerica, MA, USA), anti-STAT5,
anti-CRKL, horseradish peroxidase-linked goat anti-mouse im-
munoglobulin (Santa Cruz, Heidelberg, Germany), anti-pABL
(pY412, pY177), anti-ABL, anti-pCRKL (pY207), total caspase3,
cleaved caspase3, horseradish peroxidase-linked goat anti-rabbit
(Cell Signaling Technology, Danvers, MA, USA), anti-GAPDH
(Meridian Lifescience, Saco, ME, USA).
Experimental Design, TKI Treatment and Drug Wash-out
Procedures
If not otherwise stated, cells were seeded at a density of
56104 cells/ml in a total volume of 2 ml in cell culture media and
treated for 2 h with the respective TKI. Following treatment, cells
were washed twice with 2 ml PBS at room temperature and
subsequently re-seeded in 2 ml cell culture media. The washing
procedure was repeated twice, after 2 and 4 h, respectively. The
detailed experimental setup is described in Figure 1.
Cell Lysate Preparation and Western Blotting
26106 cells were incubated as described above. Cells were then
resuspended in 100 ml lysis buffer (20 mM Tris-HCl; pH 7.0,
150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium
orthovanadate, 10 mM NaF, 0.4x Complete [Roche Diagnostics,
Mannheim, Germany], 1x PhosStop [Roche Diagnostics, Mann-
heim, Germany]) and incubated for 30 min at 4uC. Lysates were
then cleared by centrifugation and subsequently subjected to SDS-
polyacrylamide gel electrophoresis (PAGE) and blotted onto
nitrocellulose membranes (ECL membrane, Amersham, Freiburg,
Germany) using an SDS electroblotting system (BioRad, Munich,
Germany). Membranes were blocked with PBS/0.5% Tween/5%
nonfat dry-milk for 1 h, incubated with primary antibody
overnight at 4uC in blocking solution and washed twice in PBS/
0.5% Tween. The membranes were then incubated for 1 h with
an appropriate secondary antibody and specific proteins were
visualized using the ECL detection system (Amersham, Freiburg,
Germany).
Flow Cytometry
DNA content analysis was performed as described previously.
[18] Briefly, cells were harvested, resuspended in 300 ml HFS-
buffer (0,05 mg/ml propidium iodide, 1 mg/ml sodium-citrate,
1 ml/ml Triton X-100), and then subjected to FACS analysis.
Annexin V staining was done using the PE Annexin V Apoptosis
Detection Kit I (Becton Dickinson, Heidelberg, Germany)
following the manufacturer’s protocol.
For intracellular staining of phospho-proteins and total-proteins
16106 cells were harvested and processed as described elsewhere.
[19].
The following antibodies were used for staining: p-
STAT5(Y694)-Alexa647, p-CRKL(Y207)-PE, ABCB1-FITC,
ABCG2-PE (Becton Dickinson, Heidelberg, Germany), cleaved
Figure 2. Repetitive washing prevents apoptosis after high-dose TKI pulse-exposure. To analyze for residual TKI activity upon HD-TKI
pulse-exposure, we employed repetitive wash-out procedures and exposure of previously untreated cells to cell culture supernatants. Therefore,
56104 cells/ml were seeded in a total volume of 2 ml in RPMI 1640 supplemented with 10% FCS and treated with TKI as indicated for 2 hours. Cells
exposed to 0.35% DMSO served as controls (‘‘M’’). Then, cells were washed and replated as described in Figure 1B (‘‘1x’’, ‘‘2x’’, ‘‘3x’’; upper panel). To
test for residual TKI-activity, the cell culture supernatants were transferred to previously untreated cells (‘‘S1’’, ‘‘S2’’, ‘‘S3’’; lower panel). For further
details of the experimental procedure please refer to Figure 1B. Percentage of cells in subG1 phase was measured by flow cytometry after
propidium iodide staining 24 hours after start of TKI treatment and is depicted for Ba/F3-BCR-ABL cells (A) and K562 cells (B), respectively.
Experiments were performed in triplicate. Data are presented as mean percentage of cells in subG1 phase + SEM.
doi:10.1371/journal.pone.0040853.g002
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caspase3(asp715)-Alexa488 (Cell Signaling Technology, Danvers,
MA, USA).
Flow cytometry analysis was done using FACSDiva-Software on
a FACS Canto II cytometer (Becton Dickinson, Heidelberg,
Germany). Final data analysis was performed using FlowJo
Software (Tree Star, Ashland, Oregon, USA).
Radioactive Imatinib Uptake and Release Assay
For uptake of 14C-labeled imatinib (Novartis, Basel, Switzer-
land) 56104 cells/ml were incubated in the presence of 25 mM
14C-labeled imatinib for 2 h at 37uC. Cellular and aqueous phases
were subsequently separated by centrifugation. The supernatant
was prepared for analysis. The cell pellet was washed twice with
1 ml PBS/56104 cells as described above and samples were either
subjected to replating in TKI-free cell culture media or prepared
for analysis. Prior to measurement of intracellular imatinib
concentration 56104 cells were washed twice with 1 ml PBS
and subsequently resuspended into 1 ml of media and then mixed
with 3 ml scintillation liquid (luma safe plus, Perkin Elmer,
Rodgau, Germany). Specific activity of 14C-labeled imatinib was
measured using a Packard TriCarb 1600TR liquid scintillation
analyzer (Perkin Elmer, Rodgau, Germany). Concentrations of
imatinib in cells and supernatants were calculated using a standard
curve.
HPLC Measurements of TKIs
An Extrelut H NT 3 tube (Merck KGaA, Darmstadt, Germany)
was used for the imatinib and midostaurin extraction from
medium. 3 ml of a sample were added to the extraction tube and
after 10 minutes the extraction tube was washed with 15 ml of
diethyl-ether/ethyl-acetate (50:50, v/v) and then with 15 ml of
chloroform/isopropanol/ammonia (84:15:1, v/v/v). The solvents
were collected in a glass reaction tube and evaporated until dry.
The residue was redissolved in 200 ml of the mobile phase. For the
dasatinib extraction from medium, the same method was used
with the exception that a mixture of 2990 ml of a sample and 10 ml
of 1 mg/l D-5 Fentanyl (internal standard) was added to the
extraction tube.
Imatinib quantification in cell culture supernatants was
performed using an Agilent HPLC 1200 Series system with a
diode array detector operated at 265 nm.
For midostaurin the DAD was operated at 286 nm and the
additional detection with a FLD was accomplished with excita-
tion/emission wavelengths set at 286/386 nm. Data acquisition
and integration was performed by ChemStation for LC 3D
Systems. A Lichrospher 100-5 RP8, 25064 mm column (Ma-
cherey-Nagel GmbH & Co. KG, Du¨ren, Germany) maintained at
3061uC for imatinib and at 4061uC for midostaurin was used for
the separation. 50 ml of a prepared sample were injected into the
HPLC and eluted in a mobile phase of 0,05 M H3PO4/KH2PO4
- CH3CN (7:3, v/v) for imatinib or of CH3OH-H2O-NH3
(89,7:10:0,3, v/v/v) for midostaurin at a flow rate of 1 ml/min.
For dasatinib quantification an Agilent HPLC 1100 Series with
a PE Sciex API 2000 LC/MS/MS System was used. The detector
was operated in the MRM scan type with the 488.1/401.0
precursor/product ion for dasatinib and 342.4/188.2 for D-5
Fentanyl. Data acquisition and integration was performed by the
Analyst 1.5 software. A Zorbax SB-C18, 4.6650 mm, 5 micron
column (Agilent Technologies Deutschland GmbH, Bo¨blingen,
Germany) maintained at 4561uC was used for the separation. In
total, 20 ml of a prepared sample were injected into the HPLC and
eluted in a mobile phase consisting of A: CH3OH and B: 50 ml
0,1 M CH3COONH4+50 ml CH3CN +950 ml H2O +1 ml
CH3COOH with a A:B ratio of 7:3, v/v and a flow rate of
0,3 ml/min.
Determination of Cell Size
Ba/F3-BCR-ABL cells were identified and photographed under
a bright field fluorescence microscope (Axio Observer A1, Zeiss,
Jena, Germany) and cell diameter was measured using Meta-
MorphH image analysis software. The mean diameter of 100 cells
was used to calculate cellular volume, assuming that Ba/F3-BCR-
ABL cells are spheric.
Intracellular imatinib concentration was calculated using the
following formula:
CTKI supernatant~CTKI intracellular|Vcells|1=Vsupernatant




Data are presented as means + SEM if not otherwise stated.
Results
HD-TKI Pulse-exposure does not Alter Kinetics of
Apoptosis
In previous studies, the underlying molecular mechanism for
cell death upon high-dose TKI (HD-TKI) pulse-exposure
remained elusive.[12–14] We speculated whether HD-TKI
pulse-exposure may alter kinetics of cell death which would result
in earlier onset of irreversible commitment to apoptosis. Thus, we
treated BCR-ABL (p 210) expressing Ba/F3 cells (Ba/F3 BCR-
ABL) with high-dose and conventional dose of either imatinib or
dasatinib. Protein lysates were obtained at 0 h, 2 h, 4 h, 6, 8 h,
10 h, 12 h, and 24 h of treatment and monitored for caspase3
cleavage by immunoblotting. A rather uniform onset of caspase3
cleavage was observed after 6 to 8 h of TKI treatment,
independent of TKI concentration or inhibitor used (see Figure
S1). Thus, apparently, onset and kinetics of cell death program
upon HD-TKI pulse-exposure was not altered. Therefore, it
appeared to be unlikely that an alternative apoptotic pathway was
activated by HD-TKI pulse-exposure.
Repetitive Drug Wash-out Prevents Apoptotic Cell Death
Upon High-dose TKI Pulse-exposure
To clarify, whether the wash-out regimen used affected drug
efficacy, we set up experiments with serial drug wash-out
procedures to observe the effects on cell death: Ba/F3 BCR-
Figure 3. AnnexinV- and Cleaved Caspase3-staining after high-dose TKI pulse-exposure. To confirm results obtained with propidium
iodide staining, AnnexinV-PE staining (A) and Cleaved Caspase3-Alexa488 staining (B) of Ba/F3-BCR-ABL cells was performed at 24 hours after HD-TKI
pulse-exposure using either imatinib or dasatinib as indicated followed by repetitive wash-out as described in Figure 2. Experiments were
performed in triplicate and one representative experiment is shown.
doi:10.1371/journal.pone.0040853.g003
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ABL cells and K562 cells (a CML blast crisis cell-line) were either
treated with 25 mM imatinib or 100 nM dasatinib for 2 h followed
by three consecutive rounds of thorough medium exchange (each
consisted of 2 washing steps) at 2 h intervals. FACS analysis for
apoptotic cell death was performed at 24 h (for details see
Figure 1). In line with previously published data, apoptosis
measured as subG1-DNA content (Figure 2), AnnexinV-positivity
and caspase3 cleavage (Figure 3), respectively was efficiently
induced by HD-TKI pulse-exposure in both cell-lines (Figure 2
and Figure 3, upper panel: ‘‘1x’’) while lower TKI concentra-
tions did not result in apoptotic cell death upon pulse-exposure (see
Figure S2A). As a control, off-target effects were ruled out by
HD-TKI pulse-exposure of parental Ba/F3 cells with either
imatinib or dasatinib (see Figure S2B). Induction of apoptosis
after HD-TKI pulse-exposure could also be observed in the
context of other oncogenes: Ba/F3 FLT3-ITD cells and MV 4–
11 cells treated with midostaurin and Ba/F3 JAK2V617F cells
treated with JAK-Inhibitor I showed similar results (data not
shown). This further confirmed HD-TKI pulse-exposure induced
apoptosis as being target specific and independent of cellular
background.
Pulse-exposure using HD-TKI was previously reported to
irreversibly induce cell death. However, unexpectedly, when cells
were extensively washed a second (2 h post the initial media
exchange) and a third time (4 h post initial media exchange)
almost all cells survived HD-TKI pulse treatment and were
rescued from apoptotic cell death (Figure 2 and Figure 3, upper
panel: ‘‘2x’’ & ‘‘3x’’; Figure S3A+B). Moreover, incubation of
previously untreated cells with cell culture supernatants derived
from the second (S2) media exchange resulted in substantial
increase in the fraction of apoptotic cells (Figure 2 and Figure 3,
lower panel: ‘‘S2’’; Figure S3A+B). Similar results were obtained
using FLT3-ITD or JAK2V617F expressing cell-lines (Ba/F3
FLT3-ITD, MV4-11 and Ba/F3 JAK2V617F) which were treated
with midostaurin or JAK-inhibitor I, respectively (data not shown).
Since we employed a drug wash-out protocol that was slightly
different from previously published experimental procedures, as a
control, we performed a set of experiments following the drug
wash-out procedure published by Shah and colleagues. [12]
Employing this wash-out protocol repetitively (three times every
2 hours), we were able to confirm our findings as described above
(Figure S3A+B). These results were surprising as the first
extensive drug wash-out should have removed all biologically
active TKI. This raised the possibility that intracellular TKI
retention, leakage into the medium over time and thus prolonged
presence of biologically active TKI concentrations might be
responsible for induction of cell death upon HD-TKI pulse-
exposure.
HD-TKI Pulse-exposure Results in Prolonged Inhibition of
Intracellular Signaling Nodes
To test for residual TKI activity, we then investigated the
kinetics of inhibition of key signaling nodes (BCR-ABL, STAT5
and CRKL) in response to HD-TKI pulse-exposure. HD-TKI
exposure results in early dephosphorylation of BCR-ABL (Y412),
STAT5 (Y694), and CRKL (Y207), while BCR-ABL (Y177) did
not show significant dephosphorylation after 2 h TKI exposure
(Figure 4A, lane 8, ‘‘2 h’’). After the first round of drug wash-out
(lane 5, ‘‘1x’’), STAT5 signaling was still suppressed, while CRKL
appeared to be largely rephosphorylated again. These effects were
seen with both imatinib and dasatinib. Using imatinib, analysis of
BCR-ABL phosphorylation (Y412) showed strong inhibition of
autophosphorylation and BCR-ABL (Y412) remained dephos-
phorylated after the first round of drug wash-out, while this was
less evident using dasatinib (Figure 4A, ‘‘1x’’). To achieve better
quantitation of signaling events upon drug wash-out, we
performed multiparameter intracellular flow cytometry using
phospho-specific antibodies against CRKL and STAT5. These
experiments confirmed our western blot data, demonstrating
strong dephosphorylation of STAT5 and only slight dephosphor-
ylation of CRKL after the first drug wash-out upon HD-TKI
pulse-exposure (Figure 4B, ‘‘1x’’).
Recovery of STAT5-phosphorylation levels correlated well with
rescue from apoptotic cell death: We observed gradual reappear-
ance of STAT5-phosphorylation signals after the second round of
drug wash-out (‘‘2x’’) reaching complete recovery of phosphory-
lation signals in all cell-lines tested upon the third round (‘‘3x’’) of
media exchange (Figure 4B). At the same time, the proportion of
apoptotic cells decreased accordingly (Figure 2 and Figure 3).
As an internal control, incubation of previously untreated cells
with supernatants derived from the corresponding washing steps 1
(S1), 2 (S2) and 3 (S3) perfectly mirrored the results observed in
washed cells: phosphorylation signals in S1 resemble those after
2 h TKI treatment, phosphorylation signals in S2 resemble those
in ‘‘1x’’, and phosphorylation signals in S3 resemble those in ‘‘2x’’
(Figure 4A). These data could also be confirmed independently
using K562 cells (Figure S4A). Again, observation of biological
activity in supernatants 2 (S2) and 3 (S3) was surprising as the first
extensive washing procedure should have removed all remaining
biologically active TKI. This indicates an abundance of active
TKIs in supernatants obtained after drug wash-out. Thus, in line
with data presented above, these results suggest intracellular
retention of TKIs which is released into the re-plating media over
time.
BCR-ABL Signaling Nodes Exhibit Different Kinetics upon
TKI Exposure
Next, we investigated biochemical dose response of phospho-
tyrosine residues of BCR-ABL (Y412 and Y177), CRKL and
STAT5 in Ba/F3-BCR-ABL and K562 cells upon TKI exposure
Figure 4. Recovery kinetics of intracellular signaling pathways upon HD-TKI pulse-exposure. (A) Ba/F3-BCR-ABL cells were treated either
with 25 mM imatinib or with 100 nM dasatinib for 2 hours followed by drug wash-out and consecutive replating as described in Figure 1B.
Untreated cells served as positive controls for phosphorylation signals (‘‘M’’). Cells treated continuously for 2 hours or 10 hours (2 h and 10 h) served
as positive controls for dephosphorylation of intracellular signalling pathways. ‘‘M’’: medium; ‘‘1x’’, ‘‘2x’’, ‘‘3x’’: Cells were treated with HD-TKI for 2 h
and drug wash-out was performed 1–3x in 2 h intervals, respectively. Lysates were prepared 2 h after drug wash-out, allowing for recovery of
phosphorylation signals in case of absent TKI activity. ‘‘S1’’, ‘‘S2’’, ‘‘S3’’: Lysates were prepared upon incubation of previously untreated cells for 2 h
with the respective cell culture supernatants obtained during each washing procedure. (B) FACS analysis of Ba/F3-BCR-ABL cells after HD-TKI
exposure followed by repetitive drug wash-out (‘‘1x’’, ‘‘2x’’, ‘‘3x’’) using phosphorylation-specific antibodies against CRKL (upper panel) and STAT5
(lower panel). Cells were treated with respective TKI for 2 h as indicated and washed as explained in Figure 1B. Two hours after each washing step
cells were fixed and permeabilized. Antibody staining was performed in parallel with p-CRKL-Alexa488 and p-STAT5-Alexa647 antibody. Untreated
cells served as a control for phosphorylation signals. All experiments were performed at least in triplicate and one representative experiment is
shown.
doi:10.1371/journal.pone.0040853.g004
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Figure 5. Kinetics and dynamics of BCR-ABL signaling upon tyrosine-kinase inhibition. K562 cells were treated with increasing
concentrations of tyrosine kinase inhibitors. Untreated cells served as a control. For analysis of signaling pathway inhibition cells were either lysed for
Western Blot analysis or fixed for FACS. (A): Left panel: Western Blot analysis of signaling pathway inhibition after exposure of Ba/F3-BCR-ABL cells to
imatinib for 2 h. Right panel: FACS analysis of STAT5 and CRKL inhibition using phosphorylation-specific antibodies. To assess signaling dynamics, this
analysis was performed at three different time-points (0.3, 2, and 12 h). (B) The same analysis was performed using the second-generation BCR-ABL
tyrosine kinase inhibitor dasatinib. Experiments were performed at least in triplicate and one representative experiment is shown.
doi:10.1371/journal.pone.0040853.g005
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Figure 6. Measurement of cellular imatinib uptake and release upon HD-TKI pulse-exposure. 56104 K562 cells were treated for 2 h with
25 mM 14C-labeled imatinib in a total volume of 1 ml cell culture media followed by drug wash-out as described for Figure 1B. Specific activity of cell
culture supernatants and cell pellets was measured using a scintillation counter. Imatinib concentrations were calculated by fitting the dpm
(disintegrations per minute) values to a standard curve. All measurements were performed in triplicate. Depicted are mean values + SEM of 4
independent experiments. (A): Dynamics of cellular imatinib content was measured. Cells were pelleted and washed according to our drug wash-out
protocol immediately at the end of the incubation period (end of exposure, ‘‘EOE’’) and then subjected to scintillation counter assessment of cellular
imatinib uptake. In parallel, for analysis of imatinib release, cells were replated in 1 ml fresh cell culture media and 0, 15, 30, and 120 min after
replating cells were again pelleted, washed and then subjected to measurement in a scintillation counter. (B): Corresponding dynamics of imatinib
concentration in cell culture supernatants upon HD-TKI pulse-exposure followed by drug wash-out. Measurement of cell culture supernatants
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(Figure 5 and Figure S4B). Using Western blotting and
intracellular phospho-flow analysis, we observed a rapid down-
regulation of STAT5-phosphorylation after 20 min exposure to
low TKI concentrations (0.25 mM imatinib or 1 nM dasatinib)
with complete inhibition of STAT5-phosphorylation occurring at
higher concentrations (Figure 5). At the same time, CRKL-
phosphorylation remained almost unchanged following exposure
to low imatinib (0.25 mM) or dasatinib (1 nM) concentrations
(Figure 5). A slight decrease in CRKL-phosphorylation was
observed upon exposure to 2.5 mM imatinib or 10 nM dasatinib.
Complete dephosphorylation of CRKL was achieved upon
exposure to very high concentrations of imatinib (25 mM) or
dasatinib (100 nM) only (Figure 5). When investigating later
time-points (2 h and 12 h), we did not observe obvious changes in
CRKL-phosphorylation levels as compared to the 0.3 h time-point
(Figure 5). Looking at BCR-ABL-phosphorylation itself, we
confirmed our previous observation that BCR-ABL (Y412)
behaves similarly to STAT5, while BCR-ABL (Y177) exhibits
only minor phosphorylation changes at least at the 2 h time-point
examined by Western blot in this study (Figure 5). In summary,
our data indicate that suppression of BCR-ABL kinase activity, as
measured by dephosphorylation of BCR-ABL (Y412) and STAT5
(Y694), does not necessarily result in immediate suppression of
either CRKL (Y207)- or BCR-ABL (Y177)-phosphorylation.
Thus, in our hands, the phosphorylation status of CRKL and
BCR-ABL (Y177) did not correlate well with the presence or
absence of biologically active TKI concentrations. Taken together,
these results suggest that dephosphorylation of CRKL and BCR-
ABL (Y177) are inadequate surrogates for inhibition of BCR-ABL
kinase activity in the setting of experimental drug wash-out.
TKIs Show Intracellular Accumulation and are Released in
a Time-dependent Fashion upon HD-TKI Pulse-exposure
The findings described above suggest that the effects observed
upon HD-TKI pulse-exposure are attributable to intracellular
TKI retention resulting in prolonged inhibition of intracellular
signaling pathways. To confirm whether redistribution of TKIs
from pulse-treated cells into the re-plating medium occurs, TKI
concentrations (imatinib and dasatinib) were analyzed intracellu-
larly and in cellular supernatants.
As an initial approach, we treated K562 cells with 25 mM 14C-
labeled imatinib. Measurement of the cellular phase immediately
after our standard drug wash-out protocol (Figure 6A, ‘‘EOE’’)
revealed a dramatic cellular drug uptake: given a mean cellular
volume of 2.487610212 L/cell (see Table S1B), the intracellular
imatinib concentration (based on ‘‘EOE’’, Figure 6A) was
calculated to be about 4.2 mM. We then re-plated the cells in
cell culture medium and subsequently measured intracellular and
extracellular imatinib concentrations simultaneously at predefined
time-points (0, 15, 30, and 120 min). This resulted in almost
complete removal of imatinib in the extracellular compartment
(time-point 0 min, Figure 6B), while the intracellular drug
concentration remained relatively high (time-point 0 min,
Figure 6A). Importantly, we then observed a time-dependent
increase of extracellular imatinib concentration reaching a mean
final concentration of 0.5360.18 mM at 120 min after drug wash-
out (Figure 6B). This was paralleled by a time-dependent
decrease in cellular imatinib concentration (Figure 6A). Thus,
these findings indeed demonstrated significant TKI release from
cells into the medium. To control for technical quality of drug
wash-out, we performed up to 4 serial washing steps and measured
imatinib concentration in cell culture supernatants immediately
after resuspension of cells: We found that increasing washing steps
beyond 2 did not result in further relevant decrease of imatinib
concentration (see Figure S5). Imatinib remained detectable even
after as much as 4 washing steps suggesting continuous drug
release from intracellular reservoirs.
Next, we set up an HPLC-based method for measurement of
extracellular and intracellular TKIs to be able to measure different
TKIs without being dependent on the availability of isotope
labeled TKIs. First, we measured imatinib in cell culture
supernatants and cellular lysates to test whether it is technically
feasible to confirm the results obtained with radioactively labeled
imatinib. We found close correlation between HPLC-data and
those obtained using 14C-labeled imatinib (Figure 7A, panel I
and Table S1A). To test whether this mechanism is also operative
in an independent BCR-ABL driven cell model and in primary
human cells, we then investigated imatinib release upon HD-TKI
pulse-exposure using different cell populations: Ba/F3-BCR-ABL
cells as well as mononuclear cells from untreated CML patients
and normal CD34+ hematopoietic progenitor cells from healthy
donors exhibited the same kinetics as previously demonstrated for
K562 cells (Figure 7A, panels II–IV). Next, we evaluated a
method for extracellular and intracellular detection of dasatinib.
Similarly to imatinib, dasatinib exhibited massive intracellular
accumulation as well as slow time-dependent drug release into cell
culture media following drug wash-out. In Ba/F3-BCR-ABL cells,
dasatinib reached a final mean concentration of 1.22 nM in the
extracellular media 2 h after drug wash-out (Figure 7B, panel I).
This is well above the reported in vitro IC50 level of 0.5–1 nM.
[20,21] A similar result with even higher dasatinib levels was
obtained in normal CD34+ cells from healthy donors (Figure 7B,
panel II).
Together, these findings provide experimental evidence that
biologically active TKI is retained intracellularly upon HD-TKI
pulse-exposure in BCR-ABL positive cell-lines and in primary
human cells.
Overexpression of ABCB1 Prevents Apoptosis upon
Imatinib Pulse-exposure
ABC-family transporters have been reported to be involved in
active TKI efflux and TKI resistance.[22–24] For imatinib, it has
been shown that ABCB1 and ABCG2 play a major role in drug
efflux-mediated drug resistance.[24–28] If intracellular TKI
accumulation and retention indeed mediates apoptosis upon
HD-TKI pulse-exposure, we hypothesized that ABC-transporters
may prevent cells from apoptosis upon HD-TKI pulse-exposure.
Indeed, overexpression of either ABCB1 or ABCG2 in K562 cells
resulted in prevention of apoptotic cell death upon HD-imatinib
pulse-exposure (Figure 8). Addition of the ABCB1-specific
inhibitor PSC833 restored susceptibility to HD-imatinib pulse-
exposure (Figure 8 A), while treatment of K562-ABCB1 cells
with PSC833 alone did not result in any significant induction of
apoptosis (see Figure S6).
Discussion
Induction of apoptosis upon HD-TKI pulse-exposure has been
demonstrated by several groups.[12–14] Based upon these
findings, a concept of irreversible commitment to apoptosis upon
immediately after 2 h incubation with 25 mM 14C-labeled imatinib represents the amount of imatinib present in the incubation medium (‘‘EOE’’).
Intervals 0, 15, 30, and 120 min represent the time elapsed after initial drug wash-out and replating in fresh cell culture media.
doi:10.1371/journal.pone.0040853.g006
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HD-TKI pulse-exposure was proposed. However, the mechanism
of induction of apoptosis upon HD-TKI pulse-exposure remained
elusive at the molecular level. [12] This prompted us to investigate
the molecular mechanisms of cell death induced by HD-TKI
pulse-exposure in more detail. It appeared unlikely that short-term
potent kinase inhibition could initiate an irreversible cell death
program without altering onset and kinetics of apoptosis. Indeed,
the data presented here provide evidence that HD-TKI pulse-
exposure does not irreversibly initiate apoptosis, since cells can be
completely rescued by drug wash-out. Western blot experiments
confirmed persistent target inhibition after HD-TKI pulse-
exposure, with no evidence of BCR-ABL (Y412) or STAT5 re-
phosphorylation after the first round of media exchange. This
indicates substantial residual TKI activity when employing a single
drug wash-out procedure.
In line with previously published data on HD-TKI pulse-
exposure, we observed re-phosphorylation of CRKL in BCR-ABL
cells after the first drug wash-out step, while discordantly BCR-ABL
(Y412) and STAT5 were still dephosphorylated.[12–14] Interest-
ingly, BCR-ABL (Y177)-phosphorylation remained almost unaf-
fected upon TKI exposure. This suggested differential kinetics and/
or dynamics of BCR-ABL (Y412)- and STAT5-phosphorylation as
compared to CRKL- and BCR-ABL (Y177)-phosphorylation.
Employing titration experiments using increasing concentrations
of either imatinib or dasatinib, we measured STAT5- and CRKL-
phosphorylation after different incubation times. This confirmed
different kinetics as well as dynamics of STAT5- versus CRKL-
phosphorylation. This difference might translate into a low
diagnostic sensitivity for residual TKI activity in vitro, if CRKL-
phosphorylation is used as a sole test for BCR-ABL tyrosine kinase
activity. [12–14].
The apparent contradiction in our finding, that BCR-ABL
(Y177)-phosphorylation does not correlate with BCR-ABL
substrate phosphorylation is supported by recent publications.
[29] While BCR-ABL (Y177) has been shown to play a crucial role
for leukemic transformation capacity of BCR-ABL[30–33], kinase
activity of BCR-ABL and downstream signaling is mainly
regulated by BCR-ABL (Y412)-phosphorylation.[34–36] Along
this line, a recent paper demonstrated that BCR-ABL (Y177) is
phosphorylated by JAK2, and not by ABL. [29] It has been
proposed that BCR-ABL (Y177)-phosphorylation provides fine-
tuning of BCR-ABL downstream signaling rather than switching
BCR-ABL signaling on and off. [29] In our hands, STAT5 is a
useful surrogate parameter to monitor immediate effects of BCR-
ABL kinase activity as its phosphorylation positively correlates
with cell survival. Moreover, it has been demonstrated that
STAT5 signaling is indispensable for initiation and maintenance
of BCR-ABL mediated leukemic transformation.[37–40].
Results obtained by employing successive rounds of drug wash-
out suggested prolonged intracellular TKI exposure to be the
critical mechanism involved in induction of apoptosis upon HD-
TKI pulse-treatment. Dose-dependent intracellular accumulation
of TKI upon imatinib exposure has already been reported
previously. [41] Along this line, we hypothesized that pronounced
intracellular TKI-accumulation might be responsible for the
observed results. Indeed, measurements of intracellular imatinib
and dasatinib uncovered remarkable intracellular TKI accumu-
lation upon HD-TKI pulse-exposure. Moreover, intracellular TKI
accumulation is characterized by a slow time-dependent decrease
in intracellular TKI levels upon drug wash-out. This was
paralleled by a time-dependent increase of TKI concentrations
in extracellular media upon washing and re-plating of cells,
indicating release of TKI from an intracellular compartment into
the cell culture media. Consistent with this, we demonstrated that
HD-TKI pulse-exposure with imatinib was ineffective at inducing
apoptosis in cells expressing the ABC-family transporters ABCB1
or ABCG2. Of note, sensitivity to HD-TKI pulse-exposure was
restored by pharmacological inhibition of ABC-transporters.
From a clinical perspective, our findings may prove useful for
refinement of effective TKI dosing schedules, especially when
applying TKIs with short plasma half-life. Along this line, recently,
it was demonstrated that a short plasma half-life of a given
compound may not necessarily predict a deficit in terms of clinical
efficacy. [10] Our in vitro model of HD-TKI pulse-exposure
revealed a previously unrecognized pharmacokinetic interplay
between TKI concentrations in the extracellular media and
intracellular TKI concentrations when a high-dose TKI pulse is
applied. Both, dramatic intracellular TKI accumulation and
delayed TKI release strongly argue in favor of an active cellular
maintenance and/or uptake mechanism that can prevent a sudden
decrease in intracellular TKI concentration. Indeed, recently it has
been demonstrated that OCT-1 mediates cellular influx of
imatinib, and that transporter activity correlates with effica-
cy.[42–44] On the other hand, it has been shown that OCT-1 has
less impact on cellular influx of dasatinib and nilotinib. [43,45,46]
Therefore, we believe that additional drug-transporter proteins
contribute to intracellular accumulation of TKIs. However, the
data presented here is consistent with a model where intracellular
accumulation and retention of TKIs in vivo also translates into
significantly higher intracellular TKI concentrations as compared
to the extracellular medium. It is conceivable that in the setting of
high-dose pulse therapy this may then result in prolonged
intracellular TKI exposure significantly exceeding plasma half-
life of a given TKI.
In conclusion, we show that dramatic intracellular TKI
accumulation and retention result in prolonged target inhibition
which appears to be the sole underlying molecular mechanism in
HD-TKI pulse-exposure (imatinib, dasatinib) mediated induction
of apoptosis in vitro. Moreover, the data illustrate that potent but
transient kinase inhibition per se is not sufficient to irreversibly
commit oncogene transformed cells to apoptosis. As we have
observed intracellular TKI accumulation and retention in other
oncogenic kinase models such as FLT3-ITD [47] and JAK2-
V617F (data not shown), the mechanism described here may
indicate a general pharmacokinetic feature of TKIs. However, this
point clearly requires further investigation.
Based on our data presented here, monitoring both, plasma and
intracellular drug levels of imatinib and dasatinib in vivo will
provide pharmacokinetic data which may prove useful to optimize
dosing schedules in upcoming clinical trials. We speculate that
Figure 7. Measurement of TKI concentrations in cell culture supernatants using chromatographic methods. Imatinib and dasatinib
concentrations were measured in cell culture supernatants using HPLC and LC/MS/MS, respectively. The sampling procedure and time-scale were
identical to that described in Figure 5. (A) Ba/F3-BCR-ABL cells (I), K562 cells (II), primary human CML patient MNCs (III) and normal CD34+ enriched
cells (IV) were pulse exposed to 25 mM imatinib followed by drug wash-out as described in Figure 1B. (B) Ba/F3-BCR-ABL cells (I) and normal
enriched CD34+ cells (II) were pulse exposed to 100 nM dasatinib followed by drug wash-out as described in Figure 1B. The red lines represent the
in vitro IC50 for the respective TKI used. Supernatant 1 (‘‘S1’’) was measured and served as a positive control. Measurement of cell culture media taken
immediately upon replating served as a control for efficient washing (‘‘0 min’’). Depicted are mean values + SEM; at least 3 independent experiments
were performed. For primary material one representative experiment is shown.
doi:10.1371/journal.pone.0040853.g007
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Figure 8. Overexpression of ABC transporters desensitizes K562 cells to high-dose imatinib pulse-exposure. (A) K562 and K562-
ABCB1 cells were treated for 2 h with 25 mM imatinib either in the presence or absence of the ABCB1-inhibitor PSC833 Cells treated with the solvent
DMSO served as negative controls. Sub-G1 DNA content analysis was performed 24 h after beginning of TKI exposure. The mean percentage of cells
in sub-G1 phase 6 SEM is depicted. Experiments were performed in triplicate. (B) K562 and K562-ABCB1 cells were surface stained with a FITC-
labeled anti-ABCB1 antibody. Cells were analyzed by flow cytometry using a BD FACS Canto II cytometer. Overlay of measurements was performed
using FlowJo Software (Tree Star, Ashland, Oregon, USA). (C) K562 and K562-ABCG2 cells were treated with 25 mM imatinib for 2 h, followed by drug
wash-out. Cells were replated in fresh cell culture medium and samples were analyzed after 24 h by flow cytometry after propidium iodide staining.
Untreated cells (‘‘DMSO’’) and continuously treated cells (‘‘25 mM IM (24 h)’’) served as controls. Three independent experiments were performed and
the mean percentage of cells in subG1 phase + SEM is shown. (D) K562 and K562-ABCG2 cells were surface stained with a PE-labeled anti-ABCG2
antibody. Cells were analyzed by flow cytometry using a BD FACS Canto II cytometer. Overlay of measurements was performed using FlowJo
Software (Tree Star, Ashland, Oregon, USA).
doi:10.1371/journal.pone.0040853.g008
Cellular Retention of TKI and Apoptosis Commitment
PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e40853
either the design of inhibitors that accumulate and are retained in
target cells or, alternatively, co-administration of drugs which
result in intracellular enrichment of specific TKIs may improve
TKI therapy in the future.
Supporting Information
Figure S1 Onset of apoptosis is unchanged upon
exposure to high TKI concentrations. Ba/F3-BCR-ABL
cells were treated using different TKI concentrations. Cells were
lysed at different time-points using lysis buffer and prepared for
Western blot analysis. Immunoblotting was performed using
monoclonal antibodies specific for total caspase3 and cleaved
caspase3. To control for equal loading, blots were stripped and re-
probed with anti-actin antibody. (A) depicts results obtained using
imatinib (B) depicts results obtained using dasatinib. At least two
independent experiments were performed and one representative
experiment is shown.
(PDF)
Figure S2 Control cells do not reveal significant cyto-
toxic effects upon HD-TKI pulse exposure. (A) Ba/F3-
BCR-ABL cells (56104 cells/ml, total volume 2 ml) were treated
with TKI as indicated for 2 h followed by extensive drug wash-out
using 262 ml PBS. Cells were then re-seeded in 2 ml cell culture
medium without TKI. Cells exposed to 0.35% DMSO served as
controls (‘‘0 h’’). Cells continuously exposed to TKI served as
positive controls (‘‘24 h’’). Twenty-four hours after start of TKI
exposure the percentage of cells in subG1 phase was measured by
flow cytometry after propidium iodide staining. Three indepen-
dent experiments were performed. Data are presented as mean
percentage of cells in subG1 phase + SEM. (B) Ba/F3 parental
cells (56104 cells/ml, total volume 2 ml) were treated for 2 h with
TKI as indicated followed by thorough drug wash-out using
262 ml PBS. Cells were then reseeded in 2 ml cell culture
medium without TKI. Twenty-four hours after start of TKI
exposure the percentage of cells in subG1 phase was measured by
flow cytometry after propidium iodide staining. At least three
independent experiments were performed and data are presented
as mean percentage of cells in subG1 phase + SEM.
(PDF)
Figure S3 Repetitive washing prevents apoptosis in
K562 cells –effect of a different wash-out protocol.
K562 cells were treated either with imatinib or dasatinib as
indicated. To control for the effects of different washing protocols,
in this case the wash-out procedure was performed as previously
described by Shah et al. 2008. In brief, cells (56104 cells/ml, total
volume 2 ml for PI staining and 20 ml for AnnexinV and cleaved
caspase3 staining) were washed three times with a volume of
medium (containing 10% FCS) that consisted of 50% of the
volume of the drug exposure. Cells were afterwards replated in
fresh medium (+10% FCS) without inhibitor. For repetitive
washing procedures under the same conditions, we generally
followed the scheme as is depicted in Figure 1B. (A) Results of PI
measurement of cells at 48 hours. Three independent experiments
were performed and data are presented as mean percentage of
cells in subG1 phase + SEM. (B) FACS measurement of AnnexinV
and cleaved caspase3 at 48 hours. The Y-axis represents forward
scatter (linear scale) and the X-axis depicts the signal intensity of
AnnexinV (left) and cleaved caspase3 (right) on a log-scale. Three
independent experiments were performed. One representative
experiment is shown.
(PDF)
Figure S4 Intracellular signaling in K562 cells upon
HD-TKI exposure –effect of a different wash-out proto-
col. K562 cells (56104 cells/ml, total volume 20 ml) were treated
with indicated TKI concentrations. Wash-out was performed as
previously described by Shah et al. 2008. In brief, cells were
washed three times with medium containing 10% FCS with a
volume of medium that consisted of 50% of the volume of the drug
exposure. Cells were afterwards replated in fresh medium (+10%
FCS) without inhibitor. For repetitive washing procedures under
the same conditions we generally followed the scheme as is
depicted in Figure 1B. (A) Western Blot analysis of important
signaling downstream nodes. Samples were lysed 2 h after each
washing step. Untreated cells served as positive controls for
phosphorylation signals. Cells treated continuously with TKI for
2 hours or 10 hours (‘‘2 h’’ and ‘‘10 h’’) served as positive controls
for TKI activity. (B) Cells were treated for 2 h with 100 nM
dasatinib, followed by serum wash-out. At various time points after
wash-out cells were lysed and prepared for western blot analysis.
Phosphotyrosine content was determined using the phosphotyr-
osine antibodies Y100 and 4G10 as well as P-BCR-ABL (Y177)
and (Y412). Antibodies against ABL and GAPDH served as
loading control.
(PDF)
Figure S5 Determination of washing efficiency.
K562 cells (56104/ ml) were pulse exposed for 2 h with 25 mM
14C-labeled imatinib followed by wash-out with PBS (1 ml per
56104 cells per washing step). Immediately after each washing
step the PBS supernatant was subjected to beta-counter analysis to
measure the concentration of remaining imatinib. After 4 washing
steps, cells were replated into TKI free media. Imatinib
concentration was then measured 2 h after the last washing step
(‘‘+120’’). Supernatant analyzed at the end of the TKI exposure
(‘‘EOE’’) represented a positive control for applied TKI. All
measurements were performed in triplicate. Depicted are mean
values + SEM of 3 independent experiments. Imatinib concen-
trations were calculated by fitting the dpm values to a standard
curve.
(PDF)
Figure S6 ABCB1 expression confers imatinib resis-
tance in K562 cells. K562 and K562-ABCB1 cells were treated
continuously either with 0.5 mM or 25 mM imatinib in the
presence or absence of 10 mM PSC833 as indicated. Cells exposed
to 0.35% DMSO or 10 mM PSC833 alone served as a control.
Samples were analyzed after 24 h by flow cytometry after
propidium iodide staining. Three independent experiments were
performed and results are shown as means 6 SEM.
(PDF)
Table S1 TKI concentrations measured by HPLC/LC-
MS/MS in cellular lysates. (A) TKI concentrations 6 SEM
measured by HPLC/LC-MS/MS in cellular lysates treated with
25 mM imatinib or 100 nM dasatinib for 2 h as indicated followed
by drug wash-out. Intracellular TKI concentrations were calcu-
lated based on the mean cellular volume. (B) Mean size in mm 6
SD of Ba/F3-BCR-ABL cells and K562 cells. In total, 100 cells of
each cell line were measured. Intracellular imatinib concentration
was calculated based on the assumption that cells are spherical
(V=4/36p6r3). Thus, the total cellular volume for 0.26106 cells
is 0.19 ml for Ba/F3-BCR-ABL cells and 0.5 ml for K562 cells.
(PDF)
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